Innovative Drug Shows Promise in Managing Resistant Hypertension in Chronic Kidney Disease Patients

Recent research presented at the American Heart Association's Hypertension Scientific Sessions 2025 suggests that adding the new medication baxdrostat to standard treatment regimens may significantly improve blood pressure control and potentially slow the progression of kidney damage in individuals with chronic kidney disease (CKD) who struggle with uncontrolled hypertension. CKD and high blood pressure are intertwined conditions; when not adequately managed, they increase the risk of grave health outcomes such as heart attacks, strokes, heart failure, and further decline of kidney function. The hormone aldosterone, produced by the adrenal glands, aggravates both conditions by promoting sodium retention, which elevates water volume and blood pressure, and by causing blood vessel stiffening and kidney scarring.

The study involved 195 participants with an average age of 66, most of whom had Type 2 diabetes. All participants exhibited high systolic blood pressure despite receiving maximum tolerated doses of ACE inhibitors or angiotensin receptor blockers. They also had signs of kidney impairment, evidenced by elevated urine albumin levels and reduced kidney filtration rates. Participants were randomized to receive either low or high doses of baxdrostat or placebo, alongside their existing medications. After 26 weeks, those treated with baxdrostat experienced an average reduction of approximately 8 mm Hg in systolic blood pressure compared to placebo. Notably, urine albumin levels, a marker for kidney damage, decreased by 55% in the baxdrostat group, indicating potential kidney-protective effects.

Though some participants experienced elevated potassium levels—a known side effect—the study reported no deaths or unexpected adverse events. The findings also suggest that baxdrostat may help prevent kidney damage progression, with ongoing larger trials to confirm its long-term efficacy. Experts involved in the study emphasized that these results could mark a breakthrough in managing hypertension in CKD patients, a group often excluded from clinical trials, highlighting the medication’s safety and potential benefits.

Baxdrostat belongs to a new class of drugs that inhibit aldosterone production, offering hope for improved treatment options for high blood pressure and kidney disease. However, it is important to note that baxdrostat is not yet approved by the U.S. Food and Drug Administration, and further research is required before it becomes widely available to patients.